Table 3 Use of antiviral prophylaxis and HBV infection management in DLBCL patients receiving R-chemo
Management of HBV infection | HBsAg-pos (n = 24) | HBsAg-neg/HBcAb-pos (n = 69) | HBsAg/HBcAb double-neg (n = 149) | Unknown (n = 37) |
|---|---|---|---|---|
HBsAb positivity, n (%) | 3 (12.5) | 53 (76.8) | 58 (38.9) | 1 (2.7) |
Antiviral prophylaxis | ||||
Received antiviral prophylaxis, n (%) | 17 (70.8) | 7 (10.1) | 0 (0.0) | 1 (2.7) |
Median number of cycles administered when prophylaxis was initiated (range) | ||||
Time started with prophylaxis relative to R-Chemo (range) | 1 (1, 1) | 1 (1, 1) | – | 1 (1, 1) |
Stopped prophylaxis by 120 d after last R dose, n (%) | ||||
Antiviral treatment duration, day (range) | −1 (–20, 2)1 | 0 (−1, 0) | – | −4 (−4, −4) |
4 (16.7) | 3 (4.3) | – | 0 | |
9 (4–12)1 | 6 (1–185) | – | – | |
Monitored for serologic markers,2 n (%) | 14 (58.3) | 36 (52.2) | 68 (45.6) | 2 (5.4) |
Median interval, day (range) | 53.7 (25–205) | 37.0 (18–291) | 35.3 (21–315) | 24.0 (21–27) |
First check after R-chemo, day (range) | 26.0 (1–34) | 23.0 (1–61) | 19.0 (1–90) | 20.0 (20–20) |
Monitored for HBV DNA,3 n (%) | 18 (75.0) | 21 (30.4) | 15 (10.1) | 7 (18.9) |
Median interval, d (range) | 34.9 (22–267) | 35.6 (21–168) | 40.8 (21–136) | 40.0 (22–143) |
First check after R-chemo, d (range) | 21.5 (1–49) | 24.0 (1–61) | 4.0 (1–25) | 21.0 (20–122) |
Monitored for liver function,4 n (%) | 23 (95.8) | 65 (94.2) | 144 (96.6) | 37 (100) |
Median interval, d (range) | 29.9 (20–48) | 29.2 (21-51) | 28.4 (4–82) | 29.0 (15–61) |
First check after R-chemo, d (range) | 26.5 (20–9) | 34.0 (8–114) | 25.0 (1–117) | 22.0 (1–120) |